Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Pulmonology
•
Pulmonary Infections
•
Primary Care
What is your approach to duration of antibiotic therapy for treatment of a bacterial lung abscess?
Related Questions
How do you manage resistant infections that persist after stopping antibiotic therapy in patients with non-CF bronchiectasis?
How would you approach treatment of latent TB for patients who cannot tolerate rifamycins or isoniazid due to allergy, intolerance, or drug-drug interactions?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Do add a macrolide for immunomodulatory effect in patients with macrolide-resistant M. abscessus?
Which biomarkers or diagnostic tools do you prioritize to support the decision to start antifungal treatment in septic patients with no clear source of infection but at high risk for fungal infections?
What is the interpretation of two IGRAs with negative mitogen wells, in the absence of immunosuppression?
What is your preferred agent for fungal prophylaxis in a patient post lung transplant with abnormal LFTs?
Is there any utility to trending Histoplasma serology titers to guide duration of therapy or treatment response for pulmonary histoplasmosis with negative urine antigen?
Would you start treatment for MAC in a patient with nodular bronchiectatic disease who has demonstrated radiographic progression but remains asymptomatic and smear-negative?
